MUC16 and melanoma: As shown in Figure 3B, significant OS improvement was also observed in patients with melanoma with MUC16 mutation (median, 27.03 vs 9.73 months; hazard ratio, 0.57; 95% CI, 0.36-0.90; P = .02, log-rank test).